GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 229 filers reported holding GENMAB A/S in Q3 2023. The put-call ratio across all filers is 1.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,806 | -35.7% | 51,294 | -30.7% | 0.01% | -33.3% |
| Q2 2023 | $2,809 | -11.2% | 73,994 | -11.8% | 0.01% | -14.3% |
| Q1 2023 | $3,164 | -58.3% | 83,885 | -53.2% | 0.01% | -62.2% |
| Q4 2022 | $7,596 | -99.3% | 179,352 | +443.7% | 0.04% | +516.7% |
| Q3 2022 | $1,059,000 | +5.1% | 32,987 | +6.3% | 0.01% | +20.0% |
| Q2 2022 | $1,008,000 | -10.2% | 31,044 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $1,123,000 | -58.5% | 31,044 | -54.6% | 0.01% | -50.0% |
| Q4 2021 | $2,703,000 | -9.5% | 68,412 | 0.0% | 0.01% | -9.1% |
| Q3 2021 | $2,988,000 | +8.7% | 68,412 | +1.6% | 0.01% | +10.0% |
| Q2 2021 | $2,750,000 | +11856.5% | 67,323 | +11628.7% | 0.01% | – |
| Q4 2020 | $23,000 | -92.7% | 574 | -93.3% | 0.00% | -100.0% |
| Q3 2020 | $313,000 | +580.4% | 8,537 | +525.0% | 0.00% | – |
| Q2 2020 | $46,000 | – | 1,366 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |